Challenges and opportunities in developing targeted molecular imaging to determine inner ear defects of sensorineural hearing loss.
Nanomedicine
; 14(2): 397-404, 2018 02.
Article
em En
| MEDLINE
| ID: mdl-29074310
ABSTRACT
The development of inner ear gene carriers and delivery systems has enabled genetic defects to be repaired and hearing to be restored in mouse models. Today, promising advances in translational therapies provide confidence that targeted molecular therapy for inner ear diseases will be developed. Unfortunately, the currently available non-invasive modalities, such as Computerized Tomography scan or Magnetic Resonance Imaging provide insufficient resolution to identify most pathologies of the human inner ear, even when the current generation of contrast agents is utilized. The development of targeted contrast agents may play a critical role in determining the cause of, and treatment for, sensorineural hearing loss. Such agents should be able to pass through the cochlea barriers, possess minimal cytotoxicity, and easily conjugate to a targeting agent, without distorting the anatomic details. This review focuses on a series of contrast agents which may fit these criteria for potential clinical application.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Imagem Molecular
/
Perda Auditiva Neurossensorial
/
Orelha Interna
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article